Литература | References

484. Tornblom H., Drossman D. A. Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders. Current gastroenterology reports. 2018; 20(12): 58. Doi: 10.1007/s11894-018-0664-3

485. Lu Y., Chen M., Huang Z. et al. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis. PloS one. 2016; 11(6): e0157798. Doi: 10.1371/journal.pone.0157798

486. Talley NJ, Locke GR, Saito YA et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149(2):340-9 e2.

487. Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome foundation working team report. Gastroenterology. 2018;154(4):1140-71 e1.

488. Jiang S. M., Jia L., Liu J. et al. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World journal of gastroenterology. 2016; 22(22): 5260-5266. Doi: 10.3748/wjg.v22.i22.5260

489. Tack J., Ly H. G., Carbone F. et al. Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. Clinical gastroenterology and hepatology: the offi cial clinical practice journal of the American Gastroenterological Association. 2016; 14(3): 385-392. e4. doi: 10.1016/j.cgh.2015.09.043

490. Khalilian A., Ahmadimoghaddam, D., Saki, S. et al. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. BioPsychoSocial Med. 2021; 15: 3. Doi: 10.1186/s13030-021-00205-2

491. Balakina I. V., Mironova T., Golovanova E. N. Efficacy and safety of valdoxan in patients with irritable bowel syndrome. Zhurnal nevrologii i psikhiatrii imeni S. S. Korsakova. 2014; 114(4): 90-92.

492. Seddighnia A., Tadayon Najafabadi B., Ghamari, K. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. Journal of clinical pharmacy and therapeutics. 2020; 45(1): 97-104. Doi: 10.1111/ jcpt.13032

493. Smyla N., Stephanie E., Stephanie W. et al. Amisulpride for the prevention and treatment of postoperative nausea and vomiting: A quantitative systematic review (meta-analysis). Drugs of the Future. 2019; 44(6):453.

494. Rasheed N, Ahmad A, Singh N et al. Differential response of A 68930 and sulpiride in stress-induced gastric ulcers in rats. Eur J Pharmacol. 2010; 643 (1): 121-8.

495. El-Reshaid K, Al-Bader S. New regimen for treatment of irritable bowel syndrome with emphasis on Sulpride as the sole maintenance therapy. JDDT. 2019; 9(5):154-7.

496. Warnez S., Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC psychiatry. 2014; 14: 102. Doi: 10.1186/1471-244X-14-102

497. Gupta N., Puri S., Kumar V. et al. Olanzapine in the Treatment of Refractory Nausea and Vomiting in Palliative Care Settings. Indian journal of palliative care. 2018; 24(3): 372-374. Doi: 10.4103/IJPC.IJPC_30_18

498. Grover M, Dorn SD, Weinland SR, et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci. 2009;54:1284-91.

499. Jimenez X. F., Sundararajan T., Covington, E. C. A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/ Migraine. Th e Clinical journal of pain. 2018; 34(6): 585591. Doi: 10.1097/AJP.0000000000000567

500. Tack J., Janssen P., Masaoka T. et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clinical gastroenterology and hepatology: the offi cial clinical practice journal of the American Gastroenterological Association. 2012; 10(11): 1239-1245. Doi: 10.1016/j.cgh.2012.06.036

501. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Th erapeutic advances in drug safety. 2014; 5(1): 38-56. Doi: 10.1177/2042098613505614

502. Shafigh-Ardestani M. H., Karami-Horestani M., Emami B. et al. Evaluating the Effect of Oral Gabapentin on the Improvement of Gastrointestinal Symptoms in Patients with Functional Dyspepsia Resistant to Conventional Treatments. Advanced biomedical research. 2019; 8: 53. Doi: 10.4103/abr.abr_234_18

503. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56(9):1218-25.

504. Balon R., Sonino N., & Rafanelli C. Benzodiazepines’ Role in Managing Gastrointestinal Disorders. Psychotherapy and psychosomatics. 2021; 90(2): 81-84. Doi: 10.1159/000510686

505. Matysiak- Budnik T., et al., Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Th er. 2003; 18 (Suppl. 1): 55-62.

506. Tarnawski A. S., et al. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?, Dig Dis Sci. 2004 Feb;49(2):202-9.

507. Tanigawa T, Watanabe T, Otani K, Nadatani Y, et al. Rebamipide inhibits indomethacin- induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha- defen-sin 5. Eur J Pharmacol. 2013; 704: 64-69. doi: 10.1016/j. ejphar.2013.02.010. PMID: 23428631.

508. Kurata S., et al., Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015 Jan; 56(1): 20-27. doi: 10.3164/jcbn.14-67

509. Su Jin Hong, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Studyю Gut Liver. 2016 Nov; 10(6): 910-916.

510. Gweon TG, Park JH, Kim BW, et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro- Esophageal Reflux Disease. Gut Liver. 2018;12(1):46-50. doi:10.5009/gnl17078

511. Adachi K., et al., A study on the efficacy of rebamipide for patients with proton pump inhibitor- refractory non-erosive reflux disease Dig Dis Sci. 2012 Jun;57(6):1609-17.

512. Maradey- Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20 (1):6-16. doi:10.5056/ jnm.2014.20.1.6

513. Sawada A, Fujiwara Y, Sifrim D. Belching in Gastroesophageal Reflux Disease: Literature Review. J Clin Med. 2020 Oct 20;9(10):3360. doi: 10.3390/ jcm9103360. PMID: 33092195; PMCID: PMC7590068.

514. Taki M. et al., Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol Motil. 2019 Feb 20: e13576.

515. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta- Analysis. Dig Dis Sci. 2018 May;63(5):1250-1260. doi: 10.1007/ s10620-017-4871-9. Epub 2017 Dec 1. PMID: 29192375.

516. Rangan V, Cremonini F. Rebamipide in Functional and Organic Dyspepsia: Sometimes the Best Off ense Is a Good Defense. Dig Dis Sci. 2018 May;63(5):1089-1090. Doi:10.1007/s10620-018-4974-y. PMID: 29464582

517. Pimentel- Nunes P et al. Management of epithelial pre-cancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr; 51:365. Doi: org/10.1055/a-0859-1883

518. Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-228. doi: 10.1159/000495288. Epub 2018 Nov 28. PMID: 30485855.

519. Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, Kim SE, Jung K, Kim JS, Park JK, Bang KB, Baeg MK, Shin JE, Shin CM, Lee JY, Lim HC; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020 Jan 30;26(1):29-50. doi: 10.5056/jnm19209. PMID: 31917913; PMCID: PMC6955183.

520. Lai Y, Zhong W, Yu T, et al. Rebamipide Promotes the Regeneration of Aspirin- Induced Small-Intestine Mucosal Injury through Accumulation of в- Catenin. PLoS One. 2015;10(7): e0132031. Published. 2015 Jul 2. doi:10.1371/journal.pone.0132031

521. Jang H, Park S, Lee J, et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018 Apr;33(4):878-886. doi: 10.1111/jgh.14021. Epub 2018 Jan 19. PMID: 29047150.

522. Parfenov A. I., Belostotsky N. I., Khomeriki S. G., et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Th erapeutic Archive. 2019; 91 (2): 25-31. (in Russ.) DOI: 10.26442/00403660.2019.0 2.000123 Парфенов А. И., Белостоцкий Н. И., Хомерики С. Г., и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование // Терапевтический архив. - 2019. - Т. 91. - № 2. - C. 2531. doi: 10.26442/00403660.2019.02.000123

523. Takagi T, Naito Y, Uchiyama K, et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011;17(33):3802-9. doi:10.3748/wjg.v17.i33.3802

524. Tsukanov V. V., Onuchina E. V., Vasyutin A. V., Ton-kikh Yu. L. Experience of using ursodeoxycholic acid to dissolve gallstones. Meditsinskiy sovet = Medical Council. 2019;(21):160-165. (In Russ.) Doi: 10.21518/2079-701X-2019-21-160-165 Цуканов В. В., Онучина Е. В., Васютин А. В., Тонких Ю. Л. Опыт применения урсодезоксихолевой кислоты для растворения желчных камней. Медицинский совет. 2019;(21):160-165. doi: 10.21518/2079-701X-2019-21-160-165.

525. Gaus O. V., Akhmedov V. A. The prognosis of the litho-lytic therapy effectiveness in patients with gallstone disease associated with metabolic syndrome. Modern problems of science and education. 2016, No. 5, pp. 41-41. (In Russ.) Гаус О. В., Ахмедов В. А. Прогнозирование эффективности пероральной литолитической терапии у больных с желчнокаменной болезнью, ассоциированной с метаболическим синдромом // Современные проблемы науки и образования. -2016. - N 5. - Р. 41-47.

526. Martsevich S. Yu., Kutishenko N. P., Drozdova L. Yu., et al. Study of ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with diseases of the liver, gall bladder and/or biliary tract (the RAKURS study). Rational Pharmacotherapy in Cardiology. 2014;10(2):147-152. (In Russ.) doi: 10.20996/1819-64462014-10-2-147-152 Марцевич С. Ю., Кутишенко Н. П., Дроздова Л. Ю., Лерман О. В., Невзорова В. А., Резник И. И., Шавкута Г. В., Яхонтов Д. А. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС). Рациональная Фармакотерапия в Кардиологии. 2014;10(2):147-152. Doi: 10.20996/1819-6446-201410-2-147-152